AP NEWS
This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Globe Newswire
This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation.

Rubius Therapeutics to Participate at Upcoming Investor Conferences

February 19, 2019

CAMBRIDGE, Mass., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely new class of cellular medicines, today announced that Pablo J. Cagnoni, M.D., chief executive officer, will participate at the following investor conferences:

-- Fireside chat at the 8th Annual SVB Leerink Global Healthcare Conference, Thursday, February 28, 2019, at 10:30 a.m. ET in New York, NY -- Presentation at Cowen and Company’s 39th Annual Health Care Conference, Tuesday, March 12, 2019, at 10:40 a.m. ET in Boston, MA

A live audio webcast will be available within the Investors & Media section of the Rubius Therapeutics website. An archived replay will be accessible for 90 days following each event. About Rubius TherapeuticsRubius Therapeutics is a biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely new class of cellular medicines. The Company’s proprietary RED PLATFORM® is designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent allogeneic cellular therapies. Rubius is leveraging three distinct therapeutic modalities — cellular shielding, potent cell-cell interaction and tolerance induction for the potential treatment of rare enzyme disorders, cancer and autoimmune diseases. The Company expects to file an Investigational New Drug application during the first quarter of 2019, for its lead program RTX-134 for the treatment of phenylketonuria. For more information, visit www.rubiustx.com or follow us on Twitter and LinkedIn.

Contacts:Lori MelançonVice President, Corporate Communications and Investor Relations+1 (617) 949-5296 lori.melancon@rubiustx.com

Media Contact: Dan Budwick1AB+1 (973) 271-6085 dan@1abmedia.com